CITIUS PHARMAC. DL -001
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related… Read more
Market Cap & Net Worth: CITIUS PHARMAC. DL -001 (47N)
CITIUS PHARMAC. DL -001 (F:47N) has a market capitalization of $26.10 Million (€25.42 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #35956 globally and #4336 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CITIUS PHARMAC. DL -001's stock price €3.29 by its total outstanding shares 7727180 (7.73 Million).
CITIUS PHARMAC. DL -001 Market Cap History: 2020 to 2024
CITIUS PHARMAC. DL -001's market capitalization history from 2020 to 2024. Data shows change from $171.52 Million to $26.10 Million (-35.46% CAGR).
CITIUS PHARMAC. DL -001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CITIUS PHARMAC. DL -001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 47N by Market Capitalization
Companies near CITIUS PHARMAC. DL -001 in the global market cap rankings as of March 19, 2026.
Key companies related to CITIUS PHARMAC. DL -001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CITIUS PHARMAC. DL -001 Historical Marketcap From 2020 to 2024
Between 2020 and today, CITIUS PHARMAC. DL -001's market cap moved from $171.52 Million to $ 26.10 Million, with a yearly change of -35.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | €26.10 Million | -80.84% |
| 2023 | €136.23 Million | -12.23% |
| 2022 | €155.20 Million | -40.70% |
| 2021 | €261.75 Million | +52.60% |
| 2020 | €171.52 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 28th, 2025 the market cap of CITIUS PHARMAC. DL -001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.10 Million USD |
| MoneyControl | $26.10 Million USD |
| MarketWatch | $26.10 Million USD |
| marketcap.company | $26.10 Million USD |
| Reuters | $26.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.